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Renin regulates blood pressure and fluid volume. In this issue of Cell Metabolism, Grobe et al. (2010) provide
convincing evidence for a new role for brain renin in metabolic rate and weight loss. Renin overexpression or
deletion peripherally from other studies suggests the opposite effect.Renin is an aspartyl protease that was first
discovered in the kidney over 100 years
ago. Thirty years elapsed until its enzyme
function in cleaving off the decapeptide
angiotensin (Ang) I from angiotensinogen
(AGT) was elucidated. Ang I is subse-
quently cleaved by angiotensin convert-
ing enzyme (ACE) to Ang II, an octapep-
tide that addresses several receptors
to mediate vasoconstriction, aldosterone
release, and salt retention. That renin
is produced elsewhere in the body (pla-
centa, gastrointestinal tract, and brain)
was a surprise (Ganten et al., 1971).What-
ever could renin be doing in the brain?
Central nervous system (CNS) blood
pressure regulation is well accepted, and
even CNS-mediated volume retention
would be possible with increased sympa-
thetic nervous system tone and vaso-
pressin release. Ang II function within
the brain had been explored by means
of intracerebroventricular and more-tar-
geted injections; the octapeptide has
a remarkable effect on drinking behav-
ior and salt appetite (Fitzsimons, 1998).
Nonetheless, local ‘‘tissue’’ renin-angio-
tensin systems have had difficulty in gain-
ing acceptance. However, in this issue,
Grobe et al. (2010) have produced new
tools to address the role of renin in the
brain.
The group generated double-trans-
genic mice expressing human renin
(hREN) from a neuron-specific (synapsin)
promoter and human AGT (hAGT) from
its own promoter (sRA mice) to emulate
brain expression, and thereby localized
the site of drinking behavior earlier (Sakai
et al., 2007). In the current study, the
authors found that sRA mice exhibited
polyuria and polydipsia. Surprisingly,
however, although sRA mice ingested
more salt, their preference for salt wasnot increased. They did have increased
sympathetic tone (direct measurement
of nerve activity), and increased hemato-
crit (8%), which was ascribed to volume
depletion since erythropoietin was not
elevated. An unexpected (and unex-
plained) finding was that extracellular
fluid osmolality was no different between
sRA and control mice. However, serum
sodium concentrations were much lower
in sRA mice, raising the question, ‘‘what
is the hidden osmole here’’? The issue is
not trivial, since clinical disturbances in
osmolality invariably track serum sodium
concentrations, unless someother ‘‘unex-
pected’’ osmole is present. Blockade of
the arginine vasopressin V1A and V2A
receptors did not elucidate this mystery
further.
sRA mice also had generous adrenal
glands and elevated steroid values.
Adrenalectomy eliminated the polydipsia
behavior; urine volume and osmolality
were returned to normal, as were sodium
losses. sRA mice were lean (by magnetic
resonance, 20% reduction in fat mass).
However, the mice ate more, had an
increased body temperature, and had
a 16% increased oxygen consumption.
The usual suspects, such as brown fat,
b-adrenergic receptors, Ang II receptors,
and uncoupling proteins, were not
responsible.
Ang II was detected at high levels in the
anteroventral third ventricle (AV3V) region
in brain homogenates. Peripheral Ang II
infusion experiments actually decreased
metabolic rate and altered the respiratory
quotient in the direction of increased
carbohydrate untilization. The sRA mice
also had higher blood pressures by
20 mm Hg. The authors next com-
pared their sRA mice to DOCA-salt, a
typical ‘‘secondary’’ hypertension model.Cell Metabolism 12,DOCA-salt mice exhibited an increase
in metabolic rate, a decrease in fat
mass, and a trend toward less brown fat.
Thus, sRA mice exhibited some of the
responses shown in this secondary-
hypertensionmodel. The data are exciting
and support a global role for a CNS renin-
angiotensin system with far-reaching
effects. The authors’ schema (their Fig-
ure 6D) concludes that increased fluid
intake, increased blood pressure, and
increased metabolic rate are a con-
sequence of increased renin-angio-
tensin-system activity in the brain, while
decreased in the periphery. From renin’s
behavior elsewhere, we could have ex-
pected the opposite.
Male mice harboring the human renin
transgene developed startling obesity
with hyperglycemia, hyperinsulinemia,
hyperleptinemia, and hyperlipidemia
(Uehara et al., 2003). We observed similar
findings in transgenic (hREN) rats that
also gained more weight than controls
(Gratze et al., 2009). Since human renin
does not cleave rat angiotensinogen,
these rats are normotensive with a normal
life span. An ACE inhibitor, a direct renin
inhibitor, and an AT1 receptor blocker
had no effect on the weight gain, and
CNS mechanisms could not explain
the effect. Jayasooriya et al. (2008) ap-
proached the problem from the opposite
direction. They studied ACE-deficient
(/) mice. Compared with wild-type
littermates, ACE/ mice had lower body
weight and a lower proportion of abdom-
inal body fat. ACE/ mice also had
greater fed-state total energy expenditure
and resting energy expenditure than wild-
type littermates. There were pronounced
increases in gene expression of enzymes
related to lipolysis and fatty acid oxidation
in the livers of ACE/mice. Interestingly,November 3, 2010 ª2010 Elsevier Inc. 423
Figure 1. Network between Circulating and Local Renin-
Angiotensin Systems in Kidney, Adrenal Gland, Adipose Tissue,
Vessels, and Brain
Renin is a circulating enzyme hormone that generates Ang II and thereby regu-
lates blood pressure and volume homeostasis. Local renin-angiotensin
systems have now been described for the brain, for the adrenal gland, within
the kidney, within the blood vessel wall, and within adipose tissues. The
system in the brain now appears to have remarkable effects on metabolism
in general.
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plasma leptin values. The de-
creased body fat in ACE/
mice seemed to be related
to a high energy expendi-
ture secondary to increased
metabolism of fatty acids in
the liver, with the additional
effect of increased glucose
tolerance. Takahashi et al.
(2007) generated Ren1c/
mice. The Ren1c/ mice
were lean, insulin sensitive,
and resistant to diet-induced
obesity without changes in
food intake and physical
activity. The authors sug-
gested that the lean pheno-
type was likely due to a higher
metabolic rate and gas-
trointestinal loss of dietary
fat. Most of the metabolic
changes in Ren1c/ mice
were reversed by Ang II
administration. The results
support a role for angiotensin
II in the pathogenesis of diet-
induced obesity and insulin
resistance.The findings from the Sigmund labora-
tory and others discussed herein under-
score a role for the renin-angiotensin
system that extends far beyond blood
pressure regulation and salt-and-water
balance, i.e., CNS regulation of metabo-
lism. Renin, AGT, and Ang II are gener-
ated inmany tissues (Figure 1). Also, intra-
cellular signaling of Ang II has been
described in vascular cells, and a novel
renin receptor, activated by renin and pro-424 Cell Metabolism 12, November 3, 2010 ªrenin, which resides in conjunction with
a vacuolar ATPase, further enhances the
complexity of this system. Unfortunately,
we have no evidence that blockade of
the renin-angiotensin system results in
thinness. Overexpression of renin in the
brain seems to have that result, albeit at
a 20 mm Hg cost in blood pressure.
What we need to learn now is, what are
the interrelationships between ‘‘brain,’’
‘‘tissue,’’ and ‘‘circulating’’ renin-angio-2010 Elsevier Inc.tensin systems? What are
the mechanisms by which
renin and its products evoke
the observations reported
here? How can we harness
these mechanisms into more
effective therapies? Evi-
dently, what we currently
have is not enough.
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